Shafique Virani - 15 Nov 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Business Officer
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
15 Nov 2023
Net transactions value
-$103,090
Form type
4
Filing time
17 Nov 2023, 17:52:08 UTC
Previous filing
18 Oct 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $39,960 +18,000 +13% $2.22 158,351 15 Nov 2023 Direct F1
transaction RXRX Class A Common Stock Sale $117,180 -18,000 -11% $6.51 140,351 15 Nov 2023 Direct F1
transaction RXRX Class A Common Stock Tax liability $25,870 -3,603 -2.6% $7.18 136,748 15 Nov 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -18,000 -4.3% $0.000000 397,469 15 Nov 2023 Class A Common Stock 18,000 $2.22 Direct F1, F4
holding RXRX Stock Option (Right to Buy) 212,507 15 Nov 2023 Class A Common Stock 0 $8.55 Direct F3
holding RXRX Stock Option (Right to Buy) 80,450 15 Nov 2023 Class A Common Stock 0 $11.40 Direct F5
holding RXRX Stock Option (Right to Buy) 5,436 15 Nov 2023 Class A Common Stock 0 $11.40 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
F2 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F3 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F4 One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.